Absci And Precisionlife Collaborated To Develop A Joint Portfolio Of AI-enabled Drug Pipeline; With This Partnership, Absci Achieves 2023 Outlook Of Ten New Active Programs Signed For The Year
Portfolio Pulse from Benzinga Newsdesk
Absci Corporation (ABSI) has partnered with PrecisionLife to develop a joint portfolio of AI-enabled drug pipeline projects. The collaboration aims to discover and develop biotherapeutics for up to five targets and indications, focusing on chronic diseases with unmet clinical needs. Both companies will share in the potential value of the programs developed.
December 20, 2023 | 12:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Absci's partnership with PrecisionLife to develop a joint AI-enabled drug pipeline could potentially accelerate the company's drug discovery process and aligns with its 2023 outlook of ten new active programs.
The partnership with PrecisionLife is directly related to Absci's core business of drug discovery and development. This collaboration is likely to be viewed positively by investors as it supports the company's strategic goals for the year and could lead to the development of valuable biotherapeutics. The news may increase investor confidence in Absci's ability to meet its 2023 outlook, potentially leading to a short-term positive impact on the stock price.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90